COMPARISON OF DIFFERENT DOSES OF RABBIT ANTI-THYMOCYTE GLOBULIN (ATG-T) AND ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) IN TBI-BASED MYELOABLATIVE CONDITIONING FOR HAPLOIDENTICAL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
EHA Library, Yue Lu, 4159799
SINUSOIDAL OBSTRUCTION SYNDROME AND OTHER OUTCOMES IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED INOTUZUMAB OZOGAMICIN BEFORE HEMATOPOIETIC CELL TRANSPLANTATION
EHA Library, David Marks, 4159800
IMPROVING LYMPHOPENIA AND REDUCING THE RISK OF INFECTION THROUGH THE INFUSION OF CD7 GENE KNOCK-OUT LYMPHOCYTES FOR R/R T-ALL AFTER CD7 CAR T CELL THERAPY
EHA Library, Jing Pan, 4159802
EXPLORATORY STUDY ON THE RELATIONSHIP BETWEEN THE EFFICACY OF BLINATUMOMAB TREATMENT AND T CELL FUNCTION IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA USING THE FULL-SPECTRUM FLOW CYTOMETRY ANALYSIS
EHA Library, Ruidong Zhang, 4159803
USP7 MUTATIONS PREDICT ADVERSE LONG-TERM OUTCOMES IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKAEMIA AND LYMPHOMA
EHA Library, fengfeng niu, 4159804
KTE-X19 IN RELAPSED OR REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CHINESE POPULATION: A PHASE II MULTICENTER STUDY
EHA Library, Meng Lv, 4159810
VARS: A VENETOCLAX/AZACITIDINE SCRNA-SEQ RESISTANCE SIGNATURE ASSOCIATED WITH TREATMENT RESPONSE IN ACUTE MYELOID LEUKEMIA
EHA Library, Anne Merbach, 4159811
COMPREHENSIVE MULTI-OMICS PROFILING REVEALS THE DISTINCT EOMAST-LIKE CELLULAR SUBSET IN T(8;21) ACUTE MYELOID LEUKEMIA WITH CLINICAL SIGNIFICANCE
EHA Library, Yu Liu, 4159812
UNCOVERING CD180 AS A NOVEL MARKER AND THERAPEUTIC TARGET OF CHEMORESISTANCE AND RELAPSE IN KMT2A-REARRANGED PAEDIATRIC AML.
EHA Library, Madonna Eltoukhy, 4159815
A NOVEL ROLE FOR TRANSCRIPTION FACTOR NFE2 IN REGULATING REDOX RESPONSES AND CHEMOTHERAPY RESISTANCE IN ACUTE MYELOID LEUKEMIA
EHA Library, Anne Marie Staehle, 4159817
PROTEIN S-ACYLATION DYNAMICS PROVIDE METABOLIC FLEXIBILITY TO ACUTE MYELOID LEUKEMIA CELLS
EHA Library, Nick van Gastel, 4159818
TARGETING ZEB1 TO ENHANCE MENIN-INHIBITOR SENSITIVITY IN KMT2A-MLLT3 ACUTE MYELOID LEUKEMIA THROUGH MODULATION OF MICRORNA-204
EHA Library, Liam MacPhee, 4159821
OVERCOMING VENETOCLAX RESISTANCE: SYNERGISTIC POTENTIAL OF RVU120, A CDK8/CDK19 INHIBITOR, IN COMBINATION TREATMENT.
EHA Library, Urszula Pakulska, 4159822
MULTIMODAL MACHINE LEARNING DECODES TRANSCRIPTION FACTORS-DRIVEN NK CELL DYSFUNCTION IN AML: A SINGLE-CELL TRANSCRIPTOMIC ROADMAP FOR PRECISION IMMUNOTHERAPY
EHA Library, jiaxiu Ma, 4159823
VENETOCLAX 50 MG WITH AZOLE VS. 400 MG WITHOUT AZOLE: COMPARABLE CLINICAL EFFICACY DESPITE LOWER DRUG EXPOSURE PROFILES—A PROSPECTIVE STUDY ON PHARMACOKINETICS, EFFICACY, AND TOXICITY IN NEWLY DIAGNOSED AML PATIENTS
EHA Library, Rudra Swain, 4159824
HARNESSING ENGINEERED INVARIANT NATURAL KILLER T CELLS (INKT CELLS) AGAINST CD117: A NOVEL STRATEGY FOR TREATING ACUTE MYELOID LEUKEMIA
EHA Library, chaiyaporn boonchalermvichian, 4159826
COMPUTATIONAL MEASURABLE RESIDUAL DISEASE ASSESSMENT IMPROVES RELAPSE PREDICTION IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE VALIDATION IN THE HOVON-SAKK-132 TRIAL
EHA Library, Tim Mocking, 4159828
TARGETING MUTANT ISOCITRATE DEHYDROGENASE THROUGH FRUCTOSE METABOLISM
EHA Library, Angela Maria Savino, 4159829
KMT2E EXPRESSION DEFINES A SUBSET OF LEUKEMIC STEM CELLS WITH OXPHOS DEPENDENCE AND THERAPEUTIC SENSITIVITY TO RETINOIC ACID AND PARP1 INHIBITION
EHA Library, Luise Albuquerque-Simões, 4159830
REFINING AML PATIENTS' KARYOTYPES USING OPTICAL GENOME MAPPING. UNRAVELING CRYPTIC ALTERATIONS AND DECIPHERING COMPLEX KARYOTYPES.
EHA Library, Neus Torres Hernández, 4159833
SORAFENIB REVERSES VENETOCLAX SECONDARY RESISTANCE IN ACUTE MYELOID LEUKAEMIA VIA DOWNREGULATION OF THE RAS-RAF-MEK-ERK SIGNALLING PATHWAY
EHA Library, zhangbiao long, 4159835
INTRACELLULAR SIGNALING SIGNATURES IN THE MONOCYTIC COMPARTMENT DISTINGUISH ACUTE MYELOID LEUKEMIA FROM HEALTHY PERIPHERAL BLOOD AND BONE MARROW
EHA Library, Oriol Castells, 4159840
LONG-READ SEQUENCING REVEALS THE LANDSCAPE OF ABERRANT SPLICING IN DDX41 MUTATED AML
EHA Library, Carolin Seeling, 4159841
PROTEIN ARGININE METHYLTRANSFERASE (PRMT2) IS INVOLVED IN JNK SIGNALING AND CYTOSKELETON REORGANIZATION BY COOPERATING WITH VAV1 AND WASP/WIPF1 IN ACUTE MYELOBLASTIC LEUKEMIA
EHA Library, Denis MASNIKOV, 4159842
IDH1/2-MUTATED AML: MOLECULAR PROFILE AND PROGNOSTIC IMPACT OF IDH1/2-MRD IN IDH1/2-MUTATED AML FROM THE FRENCH HAUTS-DE-FRANCE AML OBSERVATORY
EHA Library, Mélinda Dantec, 4159847
VENETOCLAX SYNERGIZES WITH HK2 INHIBITOR 2 - DG IN ACUTE MYELOID LEUKEMIA VIA THE ENDOPLASMIC RETICULUM STRESS PATHWAY.
EHA Library, Menghua Sun, 4159849
FLT3 MUTATION DRIVES THE IMMUNOPHENOTYPIC SIGNATURE OF LEUKEMIC DIFFERENTIATION ARREST AND ALTERS NK CELL PROFILE IN ACUTE MYELOID LEUKEMIA
EHA Library, Allana Carvalho, 4159851
IN DEPTH CHARACTERIZATION OF COMPLEX KARYOTYPE ACUTE MYELOID LEUKEMIA (CKAML) WITH 5Q DELETIONS USING LONG READ SEQUENCING TECHNOLOGIES
EHA Library, Anna Dolnik, 4159852
THE SYK INHIBITRO BAY 61-3606 DIHYDROCHLORIDE INDUCES APOPTOSIS OF ACUTE MYELOID LEUKEMIA CELLS BY MODULATING PI3K/AKT?NF/κB PATHWAY
EHA Library, Yanhan Zhou, 4159853
DECIPHERING CLONAL HETEROGENEITY IN AML NPM1 THROUGH SINGLE-CELL MULTI-OMIC
EHA Library, Wencke Walter, 4159854
ISOVALERYLSPIRAMYCIN I SUPPRESSES THE PROLIFERATION OF MYELOID MALIGNANCIES VIA NLRP3 INFLAMMASOME-MEDIATED PYROPTOSIS AND ROS-DRIVEN DNA DAMAGE RESPONSE.
EHA Library, wenbin yang, 4159855
IDENTIFICATION OF LEUKEMIC STEM CELLS IN AML PATIENTS BY USING NEXT-GENERATION FLOW (NGF): A PERSONALIZED BIOMARKER OF PROGNOSIS AND PROGRESSION
EHA Library, Anna Sicuranza, 4159856
NGS-DRIVEN DIGITAL PCR: A HIGHLY SENSITIVE AND EFFECTIVE TOOL FOR MONITORING MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA.
EHA Library, Mirko Farina, 4159857
CD52 PROMOTER METHYLATION PREDICTS RESPONSE TO AKT-TARGETING DRUGS IN ACUTE MYELOID LEUKEMIA
EHA Library, Carlos Quero-Dotor, 4159858
THE MOLECULAR BACKGROUND DETERMINES THE EXTENT BY WHICH LSD1 INHIBITORS SENSITIZE AML CELLS TO KINASE AND RAS INHIBITORS
EHA Library, Pedro Casado, 4159859
EPIDEMIOLOGY, CLINICAL FEATURES, AND MOLECULAR BASIS OF TTMV::RARA-DRIVEN ACUTE PROMYELOCYTIC LEUKEMIA
EHA Library, Xiaosu Zhou, 4159864
TONIC INTERFERON SIGNALING IN ACUTE MYELOID LEUKEMIA CELLS IS ASSOCIATED WITH ADVERSE DISEASE OUTCOME
EHA Library, Sophie Edtmayer, 4159867
COMPENSATORY KDM4 UPREGULATION IN IDH2-MUTANT AMLS REPRESENTS A THERAPEUTIC VULNERABILITY IN ENASIDENIB-SENSITIVE PATIENTS
EHA Library, Dominique Sternadt, 4159868
SYNERGISTIC EFFICACY OF HDACI CHIDAMIDE WITH GL-V9 BY SUPPRESSING MYBL2 EXPRESSION IN ACUTE MYELOID LEUKEMIA
EHA Library, Zheng Ge, 4159869
LIPOSOMAL MITOXANTRONE DEMONSTRATES SUPERIORITY TO TRADITIONAL MITOXANTRONE IN THE TREATMENT OF AML: DUAL MECHANISMS OF INDUCING APOPTOSIS AND BOOSTING IMMUNE RESPONSE
EHA Library, Wenqiang Qu, 4159870
LONG-TERM SURVIVAL FOR MYELOID NEOPLASMS AND NATIONAL HEALTH EXPENDITURE: A EUROCARE-6 RETROSPECTIVE, POPULATION-BASED STUDY
EHA Library, Claudia Vener, 4159872
MONITORING OF (LEUKEMIA-SPECIFIC) IMMUNE CELLS IN STAGES, TREATMENT GROUPS AND IN THE COURSE OF DISEASE AND THERAPY CONTRIBUTES TO QUANTIFY ANTILEUKEMIC POTENTIAL AND SURVIVAL IN PATIENTS WITH AML.
EHA Library, Helga Schmetzer, 4159873
CDK6 INHIBITION COUPLED WITH VITAMIN D RECEPTOR ACTIVATION SYNERGISTICALLY PROMOTES AML DIFFERENTIATION AND CELL DEATH.
EHA Library, Antonia Boudet, 4159874
THE SYNERGY OF DZNEP WITH CX-4945 AND THE CLINICAL RELEVANCE OF FOSL1 IN ACUTE MYELOID LEUKEMIA
EHA Library, Zheng Ge, 4159878
COMPREHENSIVE CHARACTERIZATION OF THE BONE MARROW MICROENVIRONMENT IDENTIFIES A DISTINCT IMMUNE SIGNATURE ASSOCIATED WITH TUMOR BURDEN IN ACUTE MYELOID LEUKEMIA
EHA Library, Nicole Fincato, 4159879
ZIFTOMENIB IN RELAPSED/REFRACTORY NPM1-MUTANT ACUTE MYELOID LEUKEMIA: PHASE 1B/2 CLINICAL ACTIVITY AND SAFETY RESULTS FROM THE PIVOTAL KOMET-001 STUDY
EHA Library, Amir Fathi, 4159880
FINAL RESULTS OF VEN A QUI TRIAL: A PHASE I-II TRIAL COMPARING VENETOCLAX WITH LOW DOSE CYTARABINE OR AZACITIDINE COMBINED WITH QUIZATINIB IN NON-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Library, Juan Miguel Bergua Burgues, 4159887
REAL-LIFE OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO MYELOPROLIFERATIVE NEOPLASIA: RESULTS OF MULTICENTRIC ENEA-STUDY.
EHA Library, Giulia Ciotti, 4159888
CLONAL ORIGIN AND EVOLUTION PATTERN UNDERLIE THE HETEROGENEITY OF FLT3-ITD-POSITIVE ACUTE MYELOID LEUKEMIA
EHA Library, Anli Lai, 4159890
TIME TO TREATMENT INITIATION AND CLINICAL OUTCOMES IN NON-INTENSIVELY TREATED ADULT ACUTE MYELOID LEUKEMIA: A PETHEMA-GPLA-ACHO-GRELAM REGISTRY STUDY
EHA Library, Eduardo Rodríguez-Arbolí, 4159893
VENETOCLAX PLUS IDARUBICIN AND CYTARABINE TREATMENT AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PEDIATRIC ACUTE MYELOID LEUKEMIA
EHA Library, shiyuan wang, 4159896
PROGNOSTIC IMPACT OF GERIATRIC ASSESSMENT IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE-VENETOCLAX
EHA Library, Marie Adeline Migeon, 4159897
EVOLUTION OF REAL-WORLD TREATMENT PATHWAYS FOR SECONDARY ACUTE MYELOID LEUKEMIA IN ENGLAND
EHA Library, Alexandrina Lambova, 4159899
EXCELLENT LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FAILING TO ACHIEVE COMPLETE MOLECULAR REMISSION
EHA Library, Yanzhi Song, 4159798
FLOW CYTOMETRY MINIMAL RESIDUAL DISEASE STATUS COMBINED WITH CYTOGENETICS RISK CLASSIFICATION PREDICTS SURVIVAL AND RELAPSE RISK IN ADOLESCENTS AND ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Jiayan Gu, 4159801
FULL PEDIATRIC INDUCTION INCLUDING HIGH DOSES OF ASPARAGINASES RESULTS IN EXCELLENT OUTCOME IN ADULT ALL PATIENTS AGED UP TO 60 YEARS, ESPECIALLY AMONG T-ALL PATIENTS
EHA Library, Paola Minetto, 4159805
INVASIVE FUNGAL DISEASE IN CHILDREN ALL RECEIVING CHEMOTHERAPY-AN ANALYISIS OF MUTI-CENTER CLINICAL TRIAL CCCG-ALL-2015
EHA Library, Xuedong Wu, 4159806
REAL WORLD ANALYSIS OF OUTCOMES USING A MODIFIED DFCI PROTOCOL FOR ADULTS WITH BCR-ABL NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA - IMPACT OF MRD
EHA Library, Joseph Brandwein, 4159808
SINGLE-CELL MULTIOMICS DATA-DRIVEN MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENT USING MULTIDIMENSIONAL FLOW CYTOMETRY (MFC) IN ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Carmen Gonzalez, 4159813
TRACKING THE STEMNESS MECHANISMS IN REFRACTORY MECOM REARRANGED ACUTE MYELOID LEUKEMIAS AT SINGLE CELL RESOLUTION
EHA Library, Ilse Kaaja, 4159814
INHIBITION OF CSF1R-CSF1 AXIS WITH AXATILIMAB EFFECTIVELY TARGETS LEUKEMIA STEM CELLS AND MONOCYTES IN BH3 MIMETICS-RESISTANT AML
EHA Library, Bing Carter, 4159816
REM-422, A SMALL MOLECULE MYB MRNA DEGRADER, DEMONSTRATES ANTI-LEUKEMIC ACTIVITY AS A MONOTHERAPY AND IN COMBINATION WITH STANDARDS OF CARE IN PRECLINICAL MODELS OF AML
EHA Library, Charles Kung, 4159819
THE GLYCOSYLTRANSFERASE MGAT1 IS A VULNERABILITY IN AML IN VITRO AND IN VIVO AND ALTERS THE AFFINITIES OF ANTI-EPITOPE DIRECTED IMMUNOTHERAPIES
EHA Library, Cosima Nather, 4159820
LOW-TOXICITY ANTIBODY DRUG-CONJUGATE THERAPY FOR AML PATIENTS TARGETING THE GLYCOSAMINOGLYCAN ONCOFETAL CHONDROITIN SULFATE
EHA Library, Priya Khadgawat, 4159825
GLYCOLYSIS-DRIVEN IMMUNE EVASION IN ACUTE MYELOID LEUKEMIA IMPAIRS MACROPHAGE-MEDIATED CLEARANCE
EHA Library, Isabel Weinhauser, 4159827
OVERCOMING VENETOCLAX RESISTANCE BY SELECTIVE PARP1 INHIBITION IN ACUTE MYELOID LEUKEMIA
EHA Library, Justinas Daraskevicius, 4159831
PRL2 IS ESSENTIAL FOR THE MAINTENANCE OF LEUKEMIA STEM CELL IN MLL GENE REARRANGEMENT ACUTE MYELOID LEUKEMIA VIA INTERACTING WITH KDM2B
EHA Library, Hongxia Chen, 4159832
LEVELS OF 91 CIRCULATING INFLAMMATORY PROTEINS AND RISK OF ACUTE MYELOID LEUKEMIA : A MENDELIAN RANDOMIZATION STUDY
EHA Library, Tao Wu, 4159836
CD39 EXPRESSION ON AML BLASTS INFLUENCES TH1 CELL DIFFERENTIATION AND PROLIFERATION VIA WNT6 AND SPP1-CD44 SIGNALING PATHWAYS WITHIN THE BONE MARROW MICROENVIRONMENT
EHA Library, Hanheng Mai, 4159837
MESENCHYMAL STROMAL CELLSPROTECT ACUTE MYELOID LEUKAEMIA CELLS FROM VENETOCLAX-INDUCED APOPTOSIS THROUGH A CD90-MEDIATED ADHESION PATHWAY
EHA Library, Karyna Volkava, 4159838
MOLECULAR PROFILING OF PEDIATRIC AML: A NEXT-GENERATION SEQUENCING APPROACH IN A SINGLE-CENTER COHORT
EHA Library, Alba Crespo-Carrasco, 4159839
TP53-MUTATED AML: A MULTI-OMICS APPROACH TO UNDERSTAND HETEROGENEITY AND THERAPEUTIC VULNERABILITIES
EHA Library, Ana RIO-MACHIN, 4159843
GENOMIC AND TRANSCRIPTOMIC DETERMINANTS ON CLINICAL OUTCOME IN AML PATIENTS WITH DNMT3A MUTATION
EHA Library, Feng-Ming Tien, 4159844
IDENTIFICATION OF NOVEL HIGH-RISK SUBTYPES BY DEVELOPMENT OF MULTI-OMICS-BASED MOLECULAR CLASSIFICATION TO GUIDE PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA
EHA Library, Runyu Yang, 4159845
SINGLE CELL SEQUENCING DECIPHERING THE HETEROGENEOUS LANDSCAPE OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH NOVEL MYB-ZFAT FUSION GENE
EHA Library, Ruijuan Li, 4159846
WOGONIN INDUCES APOPTOTIC CELL DEATH THROUGH PI3K/AKT AND MAPK/ ERK PATHWAYS AND SYNERGIZES WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA
EHA Library, Xia Jiang, 4159848
PLINABULIN AND SELUMETINIB INDUCE AAMS REPROGRAMMING INTO M1-LIKE MACROPHAGES AND REDUCE AML CELL VIABILITY
EHA Library, Lucio Henrique Sousa Pinheiro, 4159850
THE MECHANISM AND THERAPEUTIC SIGNIFICANCE OF THE HO-1/MPO AXIS IN DRIVING IMMUNE EVASION OF ACUTE MYELOID LEUKEMIA THROUGH REPROGRAMMING TUMOR-ASSOCIATED MACROPHAGE POLARIZATION
EHA Library, Jishi Wang, 4159860
OVERCOMING CHEMOTHERAPY RESISTANCE THROUGH TARGETED INHIBITION OF DNA-PK-DEPENDENT DNA REPAIR.
EHA Library, shuyu Qin, 4159861
SELINEXOR MODULATES T CELL FUNCTION AND ALLEVIATES GVHD WHILE INHIBITING AML CELL PROLIFERATION
EHA Library, Xiwen Tong, 4159862
DRUG SCREENING IN A ZEBRAFISH MODEL OF MLL-AF9-DRIVEN ACUTE MYELOID LEUKEMIA
EHA Library, Maryam Saberi, 4159863
TARGETING RIBOFLAVIN METABOLISM IN ACUTE MYELOID LEUKEMIA
EHA Library, Stefan Bjelosevic, 4159865
DEVELOPMENT OF A DUAL TARGETING CD123-CD33 CAR-T CELL THERAPY AS A BRIDGE TO ALLO-HSCT IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS
EHA Library, Vladimir Mulens-Arias, 4159866
FERROPTOSIS SENSITIVITY IN ACUTE MYELOID LEUKEMIA OPENS AVENUES FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES
EHA Library, Yara Lackousha, 4159871
VALIDATION OF A 4-GENE PROGNOSTIC INDEX IN A REAL-WORLD BRAZILIAN COHORT AND EVALUATION OF PHARMACOLOGICAL INHIBITION TO ENHANCE CHEMOTHERAPY RESPONSE IN ACUTE MYELOID LEUKEMIA
EHA Library, Maria Luiza Salustiano-Bandeira, 4159875
NOVEL THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA IDENTIFIED THROUGH MULTICENTER PROTEOME-WIDE MENDELIAN RANDOMIZATION
EHA Library, Linhui Hu, 4159876
TRANSCRIPTOMICS OF NUCLEAR FACTOR IA-MEDIATED AML LEUKEMOGENESIS UNVEIL NOVEL TARGETS FOR AML THERAPY
EHA Library, Jan-Henrik Mikesch, 4159877
LONG-TERM REAL-WORLD EXPERIENCE WITH CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND
EHA Library, Alexandrina Lambova, 4159881
AZACITIDINE IN COMBINATION WITH REDUCED DURATION VENETOCLAX IN PATIENTS WITH DE NOVO, SECONDARY, AND RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA: INTERIM ANALYSIS OF THE PROSPECTIVE NAMLG LD-VENEX TRIAL
EHA Library, Anne Louise Tølbøll Sørensen, 4159882
UPDATED RESULTS FROM THE ONGOING PHASE 1/2A STUDY OF MP0533, A TETRA-SPECIFIC DESIGNED ANKYRIN REPEAT PROTEIN (DARPIN; CD33 X CD123 X CD70 X CD3), IN PATIENTS WITH RELAPSED/REFRACTORY AML OR MDS/AML
EHA Library, Pierre Bories, 4159883
UPDATED SAFETY & ANTILEUKEMIC ACTIVITY DATA OF SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR INTENSIVE CHEMOTHERAPY
EHA Library, Jake Shortt, 4159884
TRANSCRIPTOMICALLY-REFINED ACUTE MYELOID LEUKEMIA, MYELODYSPLASIA-RELATED (AML-MR) REFINES SURVIVAL ASSOCIATIONS AND PRESENTS WITH DISTINCT BIOLOGICAL FEATURES
EHA Library, Lorenz Oelschlaeger, 4159885
CPX-351 IN PATIENTS WITH NEWLY DIAGNOSED POST MYELOPROLIFERATIVE NEOPLASMS ACUTE MYELOID LEUKEMIA . FINAL RESULTS OF THE CPX-TA SMP PHASE II TRIAL.
EHA Library, Sylvain Garciaz, 4159886
CONDITIONING INTENSITY, CONCURRENT NPM1 MUTATIONS, AND MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH FLT3-ITD AML UNDERGOING ALLOGENEIC TRANSPLANTATION: A POST-HOC ANALYSIS FROM BMT CTN 1506
EHA Library, Mark Levis, 4159889
STANDARD CHEMOTHERAPY AS FIRST LINE TREATMENT FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS (BPDCN) IN THE ERA OF CD123 TRAGETED THERAPIES: FINAL RESULTS OF A FRENCH PROSPECTIVE TRIAL
EHA Library, Eric Deconinck, 4159891
THE COMBINATION OF VENETOCLAX AND AZACITIDINE IS ASSOCIATED WITH A REDUCED RISK OF INFECTIOUS EVENTS COMPARED TO INTENSIVE CHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY AML. A RETROSPECTIVE STUDY BY THE FHU GOAL
EHA Library, Bobo Maxime, 4159892
VALIDATION OF GENETIC RISK CLASSIFICATION ELN 2024 IN REAL-WORLD AML PATIENTS TREATED WITH HMA AND HMA/VEN BASED REGIMENS
EHA Library, Juan Miguel Bergua Burgues, 4159894
MRD IN ACUTE MYELOID LEUKEMIA: A BABYLONIAN MISCOMMUNICATION?
EHA Library, Gwendolyn Van Gorkom, 4159895
UPDATED SAFETY AND ANTILEUKEMIC ACTIVITY DATA FOR SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Pau Montesinos, 4159898
PHASE 1/1B TRIAL OF TALAZOPARIB AND GEMTUZUMAB OZOGAMICIN IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD33+ ACUTE MYELOID LEUKEMIA
EHA Library, Ross McCauley, 4159900

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings